What kind of company is Inspira Technologies?

Inspira Technologies (Inspira Technologies Oxy B.H.N.) is a commercial-stage medical device company headquartered in Israel and listed on Nasdaq. It develops next-generation blood oxygenation and respiratory support systems designed for patients with critical respiratory failure. Its flagship product, the 'INSPIRA ART100,' has received FDA and CE clearance — in the United States for use during cardiopulmonary bypass surgery and internationally for extracorporeal membrane oxygenation (ECMO). The device offers an approach that reduces invasiveness and side effects compared with conventional mechanical ventilators. The system is also integrated with a real-time blood monitoring solution, enabling continuous patient monitoring in ICU and operating room settings. In 2025, the company secured binding purchase orders totaling approximately $49.5 million, marking its transition into full-scale commercialization.

💰 How does it make money?

Inspira Technologies' revenue remains very small, as the company is still in the early commercialization stage, but first commercial sales were recorded in 2025, and binding purchase orders of approximately $49.5 million have been secured, suggesting significant room for revenue growth going forward. Of these orders, roughly $27 million are tied to a contract with an African nation's ministry of health, while $22.5 million come from a private-sector company.

📐 Market cap and company scale

The market capitalization stands at approximately $16.5M, roughly About 0% of Samsung Electronics' market cap. The company employs 40 people people.

Inspira Technologies is a micro-cap medical device company with a market cap of $16.5M, with a workforce of 40 people engineers, clinical specialists, and sales personnel focused on product development and global commercialization. While its scale is far smaller than that of major respiratory support device makers, it occupies a differentiated niche positioning relative to incumbent ECMO and ventilator manufacturers.

📈 Inspira Technologies outlook and stock trajectory

Inspira Technologies promotes itself as a next-generation respiratory support platform designed to overcome the limitations of conventional mechanical ventilators — namely complications — and the technical complexity of ECMO, targeting the structurally growing severe respiratory failure treatment market. The pace at which binding purchase orders convert into recognized revenue, along with the speed of commercialization in new markets such as Africa and the Middle East, will be the key short-term earnings drivers. Its digital respiratory support platform strategy, which integrates real-time blood monitoring capabilities, forms the long-term growth narrative. Until revenue scale meaningfully expands, metrics such as gross margin (-154.7%), operating margin (-4710.7%), earnings per share ($-0.45), and return on equity (-397.9%) are likely to remain in territory reflecting losses and a heavy R&D burden.

⚔️ Key competitive strengths and risks

Inspira Technologies is an early-commercialization company that combines the appeal of a next-generation respiratory support platform theme with the momentum of large purchase orders, but revenue conversion pace and funding risk remain the primary variables.

Competitors and related beneficiary stocks

Inspira Technologies' territory overlaps with Medtronic (MDT), Getinge (GETI-B), and LivaNova (LIVN) in the respiratory support and ECMO markets, and with Masimo (MASI) and Edwards Lifesciences (EW) in the blood monitoring space. Related stocks include global medical device bellwethers Medtronic (MDT) and Edwards Lifesciences (EW).

✅ Investor checklist

If you are considering an investment in Inspira Technologies, please review the following checkpoints.

Early-commercialization medical device companies can experience sharp share price swings around major order announcements, so it is important to weigh disclosure events against fundamentals.

In summary, Inspira Technologies is an early-commercialization medical device company with a next-generation respiratory support platform that addresses the limitations of conventional ventilators and ECMO. The pace at which purchase orders convert into revenue and the rate of hospital adoption are central to the company's enterprise value.

On US Stock Today's real-time dashboard, you can check Inspira Technologies' live quotes, technical indicators, and peer comparisons at a glance.